Sign in
CompletedPhase 2

SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Key facts

Who runs it
Beijing Suncadia Pharmaceuticals Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
353 people enrolled
Started
12 Apr 2023
Ended
25 Jun 2024
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • SHR-2004 injection
  • Enoxaparin sodium injection
Record updated
20 January 2025

Who can take part

Age
40 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Understand the research procedures and methods, volunteer to participate in the study, and sign the informed consent
  • Scheduled to undergo elective unilateral total knee arthroplayts (TKA)
  • Male or female(≥ 40 years old and < 80 years old)

Who cannot take part

  • Malignant tumor within one year of the screening
  • History of venous thromboembolism
  • Myocardial infarction, transient ischemic attack or ischemic stroke occurred within 6 months of the screening
  • Any medical history that may increase the risk of bleeding or any conditions that the investigator considers to increase the risk of bleeding
  • History of drug abuse
  • Any of the laboratory test indicators meets the following criteria:; ①estimated Glomerular Filtration Rate < 60 mL/min/1.73m2 ; ②Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal value (ULN); ③total bilirubin was > 2 times, etc
  • Unable to receive CT angiography of both lower limbs
  • Pregnant or lactating women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty

The 4 groups in the trial

  • Treatment group A: SHR-2004 injectionTreatment being tested

    Treatment: SHR-2004 injection

  • Treatment group B: SHR-2004 injectionTreatment being tested

    Treatment: SHR-2004 injection

  • Treatment group C: SHR-2004 injectionTreatment being tested

    Treatment: SHR-2004 injection

  • Treatment group D: Enoxaparin sodium injectionExisting treatment, for comparison

    Treatment: Enoxaparin sodium injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Active-comparator-controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of a Single Subcutaneous Injection of SHR-2004 in Patients Undergoing Elective Unilateral Total Knee Arthroplasty
Record updated
20 January 2025